Pharmacokinetics, Tissue Distribution, and Safety of P-Ethoxy Oligonucleotides Incorporated in Liposomes

References

• Stein C., Narayanan R. Antisense oligodeoxynucleotides. Curr. Opin. Oncol. 1994; 6: 587–594
   PubMedGoogle Scholar
• Stein C. Antisense oligodeoxynucleotides as therapeutic agents. Contemp. Oncol. 1994; 4: 31–39
   Google Scholar
• Wagner R. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994; 372: 333–335
   PubMed Web of Science ®Google Scholar
• Skorski T., Szczylik C., Malaguarnera L., Calabretta B. Gene-targeted specific inhibition of chronic myeloid cell growth by Bcr-Abl antisense oligodeoxynucleotides. Folia Histochem. Cytobiol. 1992; 29: 85–90
   Web of Science ®Google Scholar
• Szczylik C., Skorski T., Nicolaides N., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A., Calabretta B. Selective inhibition of leukemia cell proliferation by Bcr-Abl antisense oligodeoxynucleotides. Science 1991; 253: 562–565
   PubMed Web of Science ®Google Scholar
• Tari A., Arlinghaus R., Lopez-Berestein G. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells. Biochem. Biophys. Res. Comm. 1997; 235: 383–388
   PubMed Web of Science ®Google Scholar
• Vaughn J., Stekler J., Dermirdji S., Mills J., Caruthers M., Iglehart J., Marks J. Inhibition of the erb-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res. 1996; 24: 4558–4564
   PubMed Web of Science ®Google Scholar
• Eder P., DeVine R., Dagle J., Walder J. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Anti-sense Res. Dev. 1991; 1: 141–151
   PubMedGoogle Scholar
• Stein C., Cheng Y.-C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical. Science 1993; 261: 1004–1012
   PubMed Web of Science ®Google Scholar
• Thierry A., Dritschilo A. Intracellular availability of unmodified, phosphoro-thioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992; 20: 5691–5698
   PubMed Web of Science ®Google Scholar
• Bennett C., Chiang M., Chan H., Shoemaker J., Mirabelli C. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 1992; 41: 1023–1033
   PubMed Web of Science ®Google Scholar
• Ropert C., Malvy C., Couvreur P. Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: Mechanism of action. Pharmaceutical Res. 1993; 10: 1427–1433
   PubMed Web of Science ®Google Scholar
• Juliano R., Akhtar S. Liposomes as a drag delivery system for antisense oligonucleotides. Antisense Res. Dev. 1992; 2: 165–176
   PubMedGoogle Scholar
• Lappalainen K., Urtti A., Soderling E., Jaaskelainen I., Syrjanen K., Syrjanen S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim. Biophy. Acta. 1994; 1196: 201–208
   PubMed Web of Science ®Google Scholar
• Tari A., Neamati N., Andreeff M., Lopez-Berestein G. Liposomal delivery of P-ethoxy antisense oligodeoxynucleotides in chronic myelogenous leukemia. “Targeting of Drugs: Strategies for oligonucleotide and gene delivery in therapy.”, G. Gregoriadis, B. McCormack. Plenum Press, New York 1996; 163–168
   Google Scholar
• Beham A., Marin M., Fernandez A., Hermann J., Brisbay S., Tari A., Lopez-Berestein G., Lozano G., Sarkiss M., McDonnell T. Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 1997; 15: 2767–2772
   PubMed Web of Science ®Google Scholar
• Tormo M., Tari A., McDonnell T., Cabanillas F., Garcia-Conde J., Lopez-Berestein G. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk. Lymphoma, in press
   Web of Science ®Google Scholar
• Tari A., Tucker S., Deisseroth A., Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 1994; 84: 601–607
   PubMed Web of Science ®Google Scholar
• Tari A., Khodadadian M., Ellerson D., Deisseroth A., Lopez-Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk. Lymphoma. 1996; 21: 93–97
   PubMed Web of Science ®Google Scholar
• Tari A., Lopez-Berstein G. Oligonucleotide Therapy for Hematological Malignancies. J. Liposomes Res. 1997; 7: 19–30
   Google Scholar
• Altman P. The Biology Databook Editorial Board. Faseb and Pergamon Inforline, Bethesda, MD 1985
   Google Scholar
• Stewart M., Plautz G., del Buono L., Yang Z., Xu L., Gao X., Huang L., Nabel E., Nabel G. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Human Gene Ther. 1992; 3: 267–275
   PubMed Web of Science ®Google Scholar
• San H., Yang Z.-Y., Pompili V., Jaffe M., Plautz G., Xu L., Feigner J., Wheeler C., Feigner P., Gao X., Huang L., Gordon D., Nabel G., Nabel E. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Human Gene Ther. 1993; 4: 781–788
   PubMed Web of Science ®Google Scholar
• Parker S. Cancer gene therapy using plasmid DNA: safety evalutaion in rodents and non-human primates. Human Gene Ther 1995; 575–590
   PubMed Web of Science ®Google Scholar
• Xing X., Liu V., Xia W., Stephens L., Huang L., Lopez-Berestein G., Hung M.-C. Safety studies of the intraperitoneal injection of El A-liposome complex in mice. Gene Ther. 1997; 4: 238–243
   PubMed Web of Science ®Google Scholar
• Henry S., Novotny W., Leeds J., Auletta C., Kornbrust D. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 1997; 7: 503–510
   PubMedGoogle Scholar
• Henry S., Taylor J., Midgley L., Levin A., Kornbrust D. Evaluation of the toxicity of Isis 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 1997; 7: 473–481
   PubMedGoogle Scholar
• DeLong R., Nolting A., Fisher M., Chen Q., Wickstrom E., Kligshteyn M., De-Mirdji S., Caruthers M., Juliano R. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 1997; 7: 71–77
   PubMedGoogle Scholar
• Agrawal S., Tan W., Cai Q., Xie X., Zhang R. In vivo pharmacokinetics of posphorothioate oligonucleotides containing contiguous guanosines. Antisense Nucleic Acid Drug Dev. 1997; 7: 245–249
   PubMedGoogle Scholar
• Chem T.-L., Miller P., Ts'o P., Colvin O. Disposition and metabolism of oligodeoxynucleoside methylphosphonate following a single iv injection in mice. Drug Metabolism Disposition 1990; 18: 815–818
   PubMed Web of Science ®Google Scholar
• Khokhar A., Wright K., Siddik Z., Perez-Soler R. Organ distribution and tumor uptake of liposome entrapped cis-bis-neodeanoato Trans-R, R-1,2 diamino-cyclohexane platinum (II) administered intravenously and into the proper hepatic artery. Cancer Chemo. Pharmacol. 1988; 22: 223–227
   Web of Science ®Google Scholar
• Lopez-Berestein G., Rosenblum M., Sadeghi T., Mehta K. Pharmacokinae-tics, tissue distribution, and toxicology of tretinoin incorporated in liposomes. J. Liposomes Res. 1994; 4: 689–700
   Google Scholar
• Zou Y., Preibe W., Ling Y.-H., Perez-Soler R. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemo. Pharmacol. 1993; 32: 190–196
   Web of Science ®Google Scholar
• Agrawal S., Temsamani J., Tang J. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 1991; 88: 7595–7599
   PubMed Web of Science ®Google Scholar
• Litzinger D., Brown J., Wala I., Kaufman S., Van G., Farrell C., Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1996; 1281: 139–149
   PubMed Web of Science ®Google Scholar
• de Smidt P., Doan T., de Falco S., van Berkel T. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. 1991; 19: 4695–4700
   PubMed Web of Science ®Google Scholar
• Crooke S., Graham M., Zuckerman J., Brooks D., Conklin B., Cummins L., Grieg M., Guinosso C., Kornbrust D., Manoharan M., Sasmor H., Schleich T., Tivel K., Griffey R. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Therapeutics 1996; 227: 923–937
   Google Scholar